Roy A. Jensen,Lisa M. Harlan-Williams,Frank J. Schoenen,Jeffrey Aube,Gerald H. Lushington
申请号：
US13525831
公开号：
US08362072B2
申请日:
2012.06.18
申请国别(地区):
US
年份:
2013
代理人:
摘要：
A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1.
